The 2010 update of the ESC guidelines for the management of atrial fibrillation - What the changes will mean for clinicians

Circulation Journal

Volumn 74, Issue 12, 2010, Pages 2534-2537

  Knecht, Sébastien ^a   Wilton, Stephen B ^a   Haïssaguerre, Michel ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; DRONEDARONE; FLECAINIDE; PLACEBO; PROPAFENONE; SOTALOL;

ANTIARRHYTHMIC ACTIVITY; ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL HEART PACEMAKER; BLEEDING TENDENCY; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; EUROPEAN UNION; HEART ATRIUM FIBRILLATION; HUMAN; PATIENT SAFETY; PRACTICE GUIDELINE; PREDICTION; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SINUS RHYTHM; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

ATRIAL FIBRILLATION; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 78649697852     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-1030     Document Type: Article

References (16)

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998; 98: 946-952.
2. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114: e257-e354.
3. European Heart Rhythm Association, European Association for Cardio- Thoracic Surgery, Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation. Eur Heart J 2010; 31: 2369-2429.
4. Dorian P, Guerra PG, Kerr CR, O'Donnell SS, Crystal E, Gillis AM, et al. Validation of a new simple scale to measure symptoms in atrial fibrillation: The Canadian Cardiovascular Society Severity in Atrial Fibrillation Scale. Circ Arrhythmia Electrophysiol 2009; 2: 218-224.
5. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach. Chest 2010; 137: 263-272.
6. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey. Chest 2010 [E-pub ahead of print].
7. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al, the Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008; 358: 2667-2677.
8. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
9. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-1840.
10. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp- Pedersen C, et al, ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668-678.
11. Jais P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: The A4 study. Circulation 2008; 118: 2498-2505.
12. Wazni OM, Marrouche NF, Martin DO, Verma A, Bhargava M, Saliba W, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: A randomized trial. JAMA 2005; 293: 2634-2640.
13. Pappone C, Augello G, Sala S, Gugliotta F, Vicedomini G, Gulletta S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: The APAF Study. J Am Coll Cardiol 2006; 48: 2340-2347.
14. Forleo GB, Mantica M, De Luca L, Leo R, Santini L, Panigada S, et al. Catheter ablation of atrial fibrillation in patients with diabetes mellitus type 2: Results from a randomized study comparing pulmonary vein isolation versus antiarrhythmic drug therapy. J Cardiovasc Electrophysiol 2009; 20: 22-28.
15. Stabile G, Bertaglia E, Senatore G, De Simone A, Zoppo F, Donnici G, et al. Catheter ablation treatment in patients with drugrefractory atrial fibrillation: A prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 2006; 27: 216-221.
16. Themistoclakis S, Corrado A, Marchlinski FE, Jais P, Zado E, Rossillo A, et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J Am Coll Cardiol 2010; 55: 735-743.